ALBERT

Description / Table of Contents: Clinical features, diagnostic evaluation and management of COVID-19 patients -- Outbreak of COVID-19: A Detailed Overview and Its Consequences -- A paradigm gap in host-pathogen interaction studies: Lesson from the COVID-19 pandemic -- SARS/CoV-2: Behavioral Host Manipulation -- Management of COVID-19 in the Intensive Care Unit -- First wave of Covid-19 pandemic in Italy: data and evidence -- Risk factors for COVID-19: diabetes, hypertension and obesity -- Current challenges for the effective management of the COVID-19 pandemic -- COVID-19 Outbreak Challenges in Indian Migrant Pregnant and Lactating Mothers: Learnt Lesson Demands Phronesis and Hierarchical Strategies for Such Future Pandemics -- COVID-19 and Extracorporeal Membrane Oxygenation -- COVID-19's Clinical-Pathological Evidence in Relation to its Repercussion on the Central and Peripheral Nervous System -- Anatomopathological Aspects and Clinical Correlation of COVID-19: A Systematic Review -- SARS-CoV-2 liability: the hidden mystery behind its presentation in children.

Description / Table of Contents: Origin and structural biology of Novel Coronavirus (SARS-CoV-2) -- The Molecular Virology of Coronaviruses with Special Reference to SARS-CoV-2 -- Epidemiology, transmission and molecular immunopathology of SARS-CoV-2 -- Epidemiology and Etiopathogeny of Covid-19 -- Immunological and Hematological Response in COVID-19 -- Toll-like receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective -- Potential drug strategies to target Coronaviruses -- Possible therapeutic intervention strategies for COVID-19 by manipulating the cellular proteostasis network -- The potential impact of statins in the treatment of patients with COVID-19 infection -- Anticoronavirus activity of water-soluble pristine C60 fullerenes: in vitro and in silico screening -- Application of Nanoscale materials and nanotechnology against viral infection: A special focus on Coronaviruses -- Obesity: A Risk Factor for Covid-19 -- Cytokine Storm and Failed Resolution in COVID-19: Taking Cue from Multiple Sclerosis.

Description / Table of Contents: 1. Introduction on Tuberculosis: Integrated Studies for a Complex Disease -- 2. Global Tuberculosis Epidemiology -- 3. Heterogeneity in Tuberculosis -- 4. The Unequivocal Relationship between Tuberculosis and Tobacco: Integration of Two Maladies -- 5. Relationship between Pre-existing Cancer and Tuberculosis -- 6. Laboratory Diagnosis of Tuberculosis -- 7. The Role of Diagnostic Microdevices in the Fight Against Tuberculosis -- 8. Immunodiagnostics of Tuberculosis: Recent Discoveries -- 9. Role of Bronchoscopy in Diagnostics and Treatment of Tuberculosis -- 10. Diagnosis of Childhood Tuberculosis in Low- and Middle-income Countries -- 11. Pediatric Tuberculosis: Current Evidence for Laboratory Diagnosis -- 12. A Multidisciplinary Approach Towards Finding and Treating All Tuberculosis Patients -- 13. Chemotherapy for Drug-Susceptible Tuberculosis -- 14. The Pharmacokinetic and Pharmacodynamic Properties of Antitubercular Medications -- 15. Immune Approaches In Tuberculosis Treatment -- 16. Inhalation Therapy in Pulmonary Tuberculosis -- 17. Role of Micronutrients in Tuberculosis Management -- 18. Drug Resistance in Tuberculosis: Mechanisms, Diagnosis, New Responses, and the Need for An Integrated Approach -- 19. Resistance in Tuberculosis: Molecular Mechanisms and Modulation -- 20. Personalized Tuberculosis Care for Drug-Resistant Tuberculosis -- 21. Important Targets and Inhibitors of Mycobacterium Tuberculosis -- 22. P-type ATPases: A Relevant Component in Mycobacterium tuberculosis Viability -- 23. The Challenges of Antitubercular Drug Discovery -- 24. Exploring Decaprenylphosphoryl-β-D-ribose 2’-Epimerase 1 (DprE1): A Target for Anti-Tubercular Drugs -- 25. Energy Pathways in Mycobacterium Tuberculosis -- 26. Drug Discovery for Non-Tuberculous Mycobacteria: Recent Updates -- 27. Challenges for Contact Tracing and Tuberculosis Preventive Therapy Scale-up -- 28. Exploring Problematizations Underlying Tuberculosis Control Strategies: A Cross-Country Analysis of India and Kenya -- 29. Challenges in Prevention and Management of Tuberculosis -- 30. Tuberculosis in Contacts and Healthcare Workers -- 31. Tuberculosis Among People Who Use Drugs: Multilevel Considerations for Prevention, Diagnosis, and Treatment -- 32. Anti-Tumor Necrosis Factor-α Antagonists and Tuberculosis -- 33. Breast Tuberculosis -- 34. Central Nervous System Tuberculosis: Pathogenesis, Diagnosis, and Management -- 35. Pleural Tuberculosis -- 36. Ocular Tuberculosis -- 37. Ocular Tuberculosis: Biomarkers for Risk Stratification -- 38. Bone and Joint Tuberculosis -- 39. Abdominal Tuberculosis: Pathogenesis, Clinical Features, and Diagnosis -- 40. Bovine Tuberculosis at The Interface of Cattle, Wildlife, and Humans -- 41. Evolution and Molecular Characteristics of Mycobacterium Tuberculosis and Mycobacterium Bovis -- 42. Animal Tuberculosis: Gross Lesions and Anatomopathological Diagnosis -- 43. Estimation of Microbial Mutation Rates in Tuberculosis Research -- 44. The Role of Epigenetics in the Development of Anti-Tuberculosis Drug Resistance -- 45. Multiomics Integration of Tuberculosis Pathogenesis -- 46. Lung Microbiome in Tuberculosis -- 47. The Correlation of Microbiota and Host Epigenome in Tuberculosis -- 48. The Pathogenesis and Progression of Sarcoidosis from The Standpoint of Tuberculosis -- 49. Tuberculosis: A Historical and Global Bioethical Perspective -- 50. The Problem of Tuberculosis: Myths, Stigma, and Mimics -- 51. Tuberculosis: Integrated Studies for a Complex Disease 2050.

Description / Table of Contents: Part 1: Getting started -- Chapter 1: The why and the what of scientific research and publishing -- Chapter 2: Understanding research ethics -- Chapter 3: How to structure a scientific article, conference poster and presentation -- Part 2: The Hidden Bumps -- Chapter 4: Who gets authorship status? -- Chapter 5: The art of journal selection -- Chapter 6: Understanding the editor’s perspectives -- Part 3: The Destination -- Chapter 7: Converting a scientific article for the media -- Chapter 8: What are research metrics and why should I care? -- Chapter 9: Beyond your scientific publication -- Chapter 10: The Editor’s Perspective – Full-Length Interviews.

Description / Table of Contents: MATRICS – an update -- Cognitive [Computational] Neuroscience Test Reliability and Clinical Applications for Serious mental illness (CNTRaCS) Consortium: Progress and Future Directions -- Attention in Schizophrenia -- Perceptual Functioning -- Episodic Memory and Schizophrenia: From Characterization of Relational Memory Impairments to Neuroimaging Biomarkers -- Working Memory in People with Schizophrenia -- "Targeting Frontal Gamma Activity with Neurofeedback to Improve Working Memory in Schizophrenia" -- Cognitive Dysfunction as a Risk Factor for Psychosis -- Environmental Risk Factors and Cognitive Outcomes in Psychosis: Pre-, Perinatal, and Early Life Adversity -- Developmental manipulation-induced changes in cognitive functioning -- Genetic underpinnings of cognitive dysfunction in schizophrenia -- Primate models of cognitive deficit re schizophrenia -- Olfactory cognitive deficits -- Medication/Anticholinergic burden impacting cognition in schizophrenia An Update on Treatment of Cognitive Impairment Associated with Schizophrenia -- Cannabis & cognition -- Sex/gender differences -- Neuroinflammation linked to cognition.

Description / Table of Contents: Preface -- Section I Cluster and Classification Models -- Hierarchical Clustering and K-means Clustering to Identify Subgroups in Surveys (50 Patients) -- Density-based Clustering to Identify Outlier Groups in Otherwise Homogeneous Data (50 Patients) -- Two Step Clustering to Identify Subgroups and Predict Subgroup Memberships in Individual Future Patients (120 Patients) -- Nearest Neighbors for Classifying New Medicines (2 New and 25 Old Opioids) -- Predicting High-Risk-Bin Memberships (1445 Families) -- Predicting Outlier Memberships (2000 Patients) -- Data Mining for Visualization of Health Processes (150 Patients) -- Trained Decision Trees for a More Meaningful Accuracy (150 Patients) -- Typology of Medical Data (51 Patients) -- Predictions from Nominal Clinical Data (450 Patients) -- Predictions from Ordinal Clinical Data (450 Patients) -- Assessing Relative Health Risks (3000 Subjects) -- Measurement Agreements (30 Patients) -- Column Proportions for Testing Differences between Outcome Scores (450 Patients) -- Pivoting Trays and Tables for Improved Analysis of Multidimensional Data (450 Patients) -- Online Analytical Procedure Cubes for a More Rapid Approach to Analyzing Frequencies (450 Patients) -- Restructure Data Wizard for Data Classified the Wrong Way (20 Patients) -- Control Charts for Quality Control of Medicines (164 Tablet Desintegration Times) -- Section II (Log) Linear Models -- Linear, Logistic, and Cox Regression for Outcome Prediction with Unpaired Data (20, 55, and 60 Patients) -- Generalized Linear Models for Outcome Prediction with Paired Data (100 Patients and 139 Physicians) -- Generalized Linear Models for Predicting Event-Rates (50 Patients) -- Factor Analysis and Partial Least Squares (PLS) for Complex-Data Reduction (250 Patients) -- Optimal Scaling of High-sensitivity Analysis of Health Predictors (250 Patients) -- Discriminant Analysis for Making a Diagnosis from Multiple Outcomes (45 Patients) -- Weighted Least Squares for Adjusting Efficacy Data with Inconsistent Spread (78 Patients) -- Partial Correlations for Removing Interaction Effects from Efficacy Data (64 Patients) -- Canonical Regression for Overall Statistics of Multivariate Data (250 Patients) -- Multinomial Regression for Outcome Categories (55 Patients) -- Various Methods for Analyzing Predictor Categories (60 and 30 Patients) -- Random Intercept Models for Both Outcome and Predictor Categories (55 Patients) -- Automatic Regression for Maximizing Linear Relationships (55 Patients) -- Simulation Models for Varying Predictors (9000 Patients) -- Generalized Linear Mixed Models for Outcome Prediction from Mixed Data (20 Patients) -- Two Stage Least Squares for Linear Models with Problematic Predictors (35 Patients) -- Autoregressive Models for Longitudinal Data (120 Monthly Population Records) -- Variance Components for Assessing the Magnitude of Random Effects (40 Patients) -- Ordinal Scaling for Clinical Scores with Inconsistent Intervals (900 Patients) -- Loglinear Models for Assessing Incident Rates with Varying Incident Risks (12 Populations) -- Loglinear Models for Outcome Categories (445 Patients) -- More on Polytomous Outcome Regressions (450 Patients) -- Heterogeneity in Clinical Research: Mechanisms Responsible (20 Studies) -- Performance Evaluation of Novel Diagnostic Tests (650 and 588 Patients) -- Quantile - Quantile Plots, a Good Start for Looking at Your Medical Data (50 Cholesterol Measurements and 52 Patients) -- Rate Analysis of Medical Data Better than Risk Analysis (52 Patients) -- Trend Tests Will Be Statistically Significant if Traditional Tests Are not (30 and 106 Patients) -- Doubly Multivariate Analysis of Variance for Multiple Observations from Multiple Outcome Variables (16 Patients) -- Probit Models for Estimating Effective Pharmacological Treatment Dosages (14 Tests) -- Interval Censored Data Analysis for Assessing Mean Time to Cancer Relapse (51 Patients) -- Structural Equation Modeling with SPSS Analysis of Moment Structures (Amos) for Cause Effect Relationships I (35 Patients) -- Structural Equation Modeling with SPSS Analysis of Moment Structures (Amos) for Cause Effect Relationships II (35 Patients) -- Firth's Bias-adjusted Estimates for Biased Logistic Data Models (23 Challenger launchings) -- Omics Research (125 Patients, 24 Predictor Variables) -- Sparse Canonical Correlation Analysis (12209 Genes in 45 Glioblastoma Carriers) -- Eigenvalues, Eigenvectors and Eigenfunctions (45 and 250 Patients) -- Section III Rules Models -- Neural Networks for Assessing Relationships that are Typically Nonlinear (90 Patients) -- Complex Samples Methodologies for Unbiased Sampling (9,678 Persons) -- Correspondence Analysis for Identifying the Best of Multiple Treatments in Multiple Groups (217 Patients) -- Decision Trees for Decision Analysis (1004 and 953 Patients) -- Multidimensional Scaling for Visualizing Experienced Drug Efficacies (14 Pain-killers and 42 Patients) -- Stochastic Processes for Long Term Predictions from Short Term Observations -- Optimal Binning for Finding High Risk Cut-offs (1445 Families) -- Conjoint Analysis for Determining the Most Appreciated Properties of Medicines to Be Developed (15 Physicians) -- Item Response Modeling for Analyzing Quality of Life with Better Precision (1000 Patients) -- Survival Studies with Varying Risks of Dying (50 and 60 Patients) -- Fuzzy Logic for Improved Precision of Pharmacological Data Analysis (9 Induction Dosages) -- Automatic Data Mining for the Best Treatment of a Disease (90 Patients) -- Pareto Charts for Identifying the Main Factors of Multifactorial Outcomes (2000 Admissions to Hospital) -- Radial Basis Neural Networks for Multidimensional Gaussian Data (90 persons) -- Automatic Modeling for Drug Efficacy Prediction (250 Patients) -- Automatic Modeling for Clinical Event Prediction (200 Patients) -- Automatic Newton Modeling in Clinical Pharmacology (15 Alfentanil dosages, 15 Quinidine time-concentration relationships) -- Spectral Plots for High Sensitivity Assessment of Periodicity (6 Years’ Monthly C Reactive Protein Levels) -- Runs Test for Identifying Best Analysis Models (21 Estimates of Quantity and Quality of Patient Care) -- Evolutionary Operations for Health Process Improvement (8 Operation Room Settings) -- Bayesian Networks for Cause Effect Modeling (600 Patients) -- Support Vector Machines for Imperfect Nonlinear Data (200 Patients) -- Multiple Response Sets for Visualizing Clinical Data Trends (811 Patient Visits) -- Protein and DNA Sequence Mining -- Iteration Methods for Crossvalidation (150 Patients) -- Testing Parallel-groups with Different Sample Sizes and Variances (5 Parallel-group Studies) -- Association Rules between Exposure and Outcome (50 and 60 Patients) -- Confidence Intervals for Proportions and Differences in Proportions (100 and 75 Patients) -- Ratio Statistics for Efficacy Analysis of New Drugs 50 Patients) -- Fifth Order Polynomes of Circadian Rhythms (1 Patient) -- Gamma Distribution for Estimating the Predictors of Medical Outcomes (110 Patients) -- Index.

Description / Table of Contents: Chapter 1. MTOCHONRIAL NEUROLOGY: A TALE OF TWO GENOMES (Salvatore DiMauro and Emanuele Barca) -- Chapter 2. Mutations in assembly factors required for the biogenesis of mitochondrial respiratory chain (Cristina Cerqua, Lisa Buson and Eva Trevisson) -- Chapter 3. Mitochondrial DNA: defects, maintenance genes and depletion (Miguel A. Fernández-Moreno, Luis Vázquez-Fonseca, Sara Palacios Zambrano and Rafael Garesse) -- Chapter 4. Mitochondrial translation deficiencies (Veronika Boczonadi, Juliane S. Müller and Rita Horvath) -- Chapter 5. Mitochondria dynamics: definition, players and associated disorders (Maria EugeniaSoriano, Marta Carro Alvarellos, Giovanni Rigoni, and Luca Scorrano) -- Chapter 6. Coenzyme Q biosynthesis disorders (Gloria Brea-Calvo, María Alcázar-Fabra, Eva Trevisson and Plácido Navas) -- Chapter 7. Cytochrome c defects in human disease (Leonardo Salviati) -- Chapter 8. Biochemical diagnosis of mitocondrial disorders (Delia Yubero, Raquel Montero, Rafael Artuch) -- Chapter 9. Molecular genetics in the Next Generation Sequencing era (Joaquin Dopazo) -- Chapter 10. Model cells and organisms in mitochondrial diseases (Rhoda Stefanatos, Alberto Sanz, Daniel J M Fernandez-Ayala) -- Chapter 11. Therapies approaches in mitochondrial diseases (Valentina Emmanuele, Catarina M Quinzii, and Michio Hirano).

Description / Table of Contents: Introduction on Integrated Science: Multidisciplinarity and Interdisciplinarity in Health -- Cognitive Sciences as a Naturalistic Model of Interdisciplinary Approaches -- The Aesthetics of Science from the Viewpoint of Neuroscience -- Neuroscience and Quantum Physics Aspect of Human Brainwaves -- Modern Psychiatry: Confluence of Mind, Science, and Society -- Schizophrenia: A Disorder of Timing and Sensorimotor Integration during Decision-making -- Getting to Know Ourselves Through Recognizing Ourselves in Others: Neuroanatomy of Empathy in a Social Neuroscientific Model -- Why People Make Irrational Choices About Their Health? -- Adherence to Treatment: At the Interface of Biological, Medical, and Social Sciences -- Social Cognition and Food Decisions in Obesity -- Nuclear Medicine: A Transdisciplinary Field to Integrate Formal, Physical, Biological, and Medical Sciences -- Beyond the Borders of Dentistry: Interprofessional and Interdisciplinary Approach to Oral Health Promotion -- Drug Discovery in Big Pharma: Where “Birds” and “Fish” Collaborate to Find New Medicines -- A Phenomenological Analysis of the Pandemic: Philosophy and Life -- Engineering, Environment, and Health: Why interdisciplinarity matters? -- Super-spreading in Infectious Diseases: A Global Challenge for All Disciplines -- Possibility of Changes in Travel Behavior as a Consequence of the Pandemic and Teleworking -- Bringing the Two Cultures of the Arts and Sciences Together in Complex Health Interventions -- Thinking Deeper, Wider, Further: Visual Thinking for the Pandemic 3.0 and the Game-Changing Pathways ahead -- The Clinical Benefits of Art Therapy: Definition, History, and Outcomes with a Focus on Music Therapy -- When Combining Arts and Sciences Assists Medical Devices Uses: DeafSpace and Cochlear Implants -- Art, Medicine, and Public Health: Synergizing Humanistic and Medical Strategies in Managing a Pandemic -- Big Data and Artificial Intelligence for E-Health -- Artificial Intelligence in the Medical Context: Who Is the Agent in Charge? -- Ethical Deliberation on AI-Based Medicine -- Towards an Integrative and Holistic Approach to the Discipline of Health Informatics -- Integrated, Multidisciplinary, and Interdisciplinary Medical Education -- Giving Voice to Social Values in Achieving Universal Health Coverage -- Discrimination in Medical Research Sampling: Recommendations and Applications to Psychology -- Integrated Science 2050: Multidisciplinarity and Interdisciplinarity in Health.

Description / Table of Contents: 1. Introduction -- 2. Tracer technique in basic research -- 3. Tracer technique in applied research -- 4. Literature cited.

Description / Table of Contents: 1. Introduction -- Part I Transforming Research with Broad Engagement -- 2. The Transformative Power of Broadly Engaged Team Science: A Moth-er’s Quest to Understand PXE -- 3. Broadly Engaged Team Science in Neonatal Research -- 4. Patient Advocates in Cancer Care: A Rich Tradition and Evolving Role -- 5. National Kidney Foundation Patient Network -- 6. Broadly Engaged Team Science Comes to Life in a Design Lab -- 7. Tufts Center for the Study of Drug Development Employs Broadly Engaged Team Science to Explore the Challenges of Pharmaceutical Research and Development -- Part II. Integrating Communities and Stakeholders into Broadly Engaged Team Science -- 8. Social Movements and Stakeholder Engagement -- 9. A Basic Scientist’s Journey: Engaging Public Stakeholders Through Civic Science -- 10. Lessons in Public Involvement from Across the Pond -- 11. Leveling the Playing Field for Community Stakeholders: Examining Practices to Improve Engagement and Address Power Dynamics -- 12. A Theory of Stakeholder-driven Community Diffusion -- 13. Monitoring and Evaluation of Stakeholder Engagement in Health Research -- Part III. Applying Broadly Engaged Team Science: Case Studies -- 14. Insiders and Outsiders: A Case Study of Fostering Research Partnerships between Academic Health Centers and Corrections Institutions -- 15. Responding to the Community: HOPE (Healthy Outcomes from Positive Experiences) -- 16. Students as Key Collaborators in Tackling Early Stage Research Ideas -- 17. Engaging Stakeholders to Decrease Study Start-up Delays -- 18. Health Literacy and Broadly Engaged Team Science: How One Study Team Used Plain Language Principles to Share Findings with Affected Communities -- 19. Utilizing Patient Navigators to Promote Equitable and Accountable Research -- 20. Asian American Research in the Post-Atlanta Era: Driving Community-engaged Research That Is More Meaningful, Responsive, and Actionable for Local Communities -- 21. Stakeholder Engagement in Predictive Model Development for Clinical Decision Support -- Part IV. Creating an Institutional Environment of Support for Broadly Engaged Team Science -- 22. Research Administration Practices for Proposal Development and Post-Award Management of Stakeholders and Community Participants -- 23. Starting Off Right: Supporting Community Involvement in the Evaluation of Research Proposals -- 24. Role of Broadly Engaged Team Science in the Inclusion of Minority Populations as Research Participants and in All Roles on Research Teams -- 25. Rewarding Team Science in Tenure and Promotion Practices: An Operational Imperative for the Academic Research Enterprise of the 21st Century -- Epilogue.

Description / Table of Contents: Chap 1. Research Environment -- Chap 2. Training, Supervision and Mentoring -- Chap 3. Research Procedures -- Chap 4. Safeguards -- Chap 5. Data Practices and Management -- Chap 6. Collaborative Working -- Chap 7. Publication and Dissemination -- Chap 8. Reviewing, Evaluating and Editing -- Chap 9. How to deal with allegations of misconduct.